POZN (10.78)...key financial facts & stellar balance sheet. Pozen is unique as a biotech company in that they have never had to go the market for funding. Most biotech companies always sell shares to institutional investors to raise money. Pozen has been self-funded and sufficient since its existence. This is the lack of overhang that will move POZEN much higher once they obtain FDA approval for VIMOVO. The Astra Zeneca deal is only the beginning for Pozen. They are already obtaining royalties from Treximet (Glaxo-GSK). The AZ deal will be great w/ other regulatory milestones of 45 million. They will receive 20 million from U.S. approval and 25 million from European approval 2 months later. They could receive 260 million based on other milestones w/o the overhead of development. POZN will be a cash machine here soon! This is not a 1 and done company.
Market Data 
Markets 
AI
